Jamilian Mehri, Sabzevar Niloufar Kazemi, Asemi Zatollah
Endocrinology and Metabolism Research Center, Arak University of Medical Sciences, Arak, Iran.
Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran.
Horm Metab Res. 2019 Feb;51(2):100-105. doi: 10.1055/a-0749-6431. Epub 2018 Oct 4.
Data on the effects of magnesium and vitamin E co-supplementation on glycemic control and markers of cardio-metabolic risk of patients with polycystic ovary syndrome (PCOS) were collected. This investigation was conducted to evaluate the effects of magnesium and vitamin E co-supplementation on glycemic control and markers of cardio-metabolic risk in women with PCOS. This randomized, double-blind, placebo-controlled trial was carried out on 60 women with PCOS, aged 18-40 years old. Participants were randomly divided into two groups to receive 250 mg/day magnesium plus 400 mg/day vitamin E supplements or placebo (n=30 each group) for 12 weeks. Fasting blood samples were taken at baseline and after the 12-week intervention to quantify related variables. After the 12-week intervention, compared with the placebo, magnesium and vitamin E co-supplementation led to a significant reduction in serum insulin levels (-1.1±3.0 vs. +1.6±3.7 μIU/ml, p=0.003) and homeostatic model of assessment for insulin resistance (-0.2±0.7 vs. +0.4±0.9, p=0.002), and a significant increase in the quantitative insulin sensitivity check index (+0.01±0.01 vs. -0.009±0.02, p=0.003). Furthermore, magnesium plus vitamin E supplementation significantly decreased serum triglycerides (-15.0±24.4 vs. +6.7±22.2 mg/dl, p=0.001) and VLDL-cholesterol concentrations (-3.0±4.9 vs. +0.6±2.4 mg/dl, P=0.01) compared with the placebo. A trend toward a greater decrease in total cholesterol levels was observed in magnesium plus vitamin E group compared to placebo group (-7.0±32.6 vs. +8.1±26.6 mg/dl, p=0.05). In conclusion, magnesium and vitamin E co-supplementation for 12 weeks to PCOS women had beneficial effects on parameters of insulin metabolism and few markers of cardio-metabolic risk.
收集了关于联合补充镁和维生素E对多囊卵巢综合征（PCOS）患者血糖控制及心脏代谢风险标志物影响的数据。本研究旨在评估联合补充镁和维生素E对PCOS女性血糖控制及心脏代谢风险标志物的影响。这项随机、双盲、安慰剂对照试验在60名年龄在18至40岁的PCOS女性中进行。参与者被随机分为两组，分别接受每日250毫克镁加400毫克维生素E补充剂或安慰剂（每组n = 30），为期12周。在基线和12周干预后采集空腹血样以量化相关变量。12周干预后，与安慰剂组相比，联合补充镁和维生素E导致血清胰岛素水平显著降低（-1.1±3.0对+1.6±3.7 μIU/ml，p = 0.003）以及胰岛素抵抗的稳态模型评估显著降低（-0.2±0.7对+0.4±0.9，p = 0.002），并且定量胰岛素敏感性检查指数显著升高（+0.01±0.01对-0.009±0.02，p = 0.003）。此外，与安慰剂相比，补充镁加维生素E显著降低了血清甘油三酯（-15.0±24.4对+6.7±22.2 mg/dl，p = 0.001）和极低密度脂蛋白胆固醇浓度（-3.0±4.9对+0.6±2.4 mg/dl，P = 0.01）。与安慰剂组相比，镁加维生素E组总胆固醇水平有更大降低的趋势（-7.0±32.6对+8.1±26.6 mg/dl，p = 0.05）。总之，对PCOS女性联合补充镁和维生素E 12周对胰岛素代谢参数及一些心脏代谢风险标志物有有益影响。
